t
Diaceutics PLC issued a Block Listing Return on 7 October 2026 for its UK and Global Share Incentive Plan (SIP), Employee Share Option Plan (ESOP), and Unapproved Share Option Plan (USOP). From 7 April 2026 to 6 October 2026, 316,969 Ordinary Shares were issued under these schemes, leaving 916,094 Ordinary Shares unissued from the schemes, with a total of 85,234,252 Ordinary Shares of £0.002 each in issue at the period's end.
| Date | 7 Oct 2026 |
| Time | 07:00:04 |
| Category | Miscellaneous |
| ID | 6627X |
Diaceutics PLC
BLOCK LISTING RETURN
New York, Belfast and London, 7 October 2026 - Diaceutics PLC (AIM: DXRX), the intelligence and engagement company unlocking the full potential of diagnostic-driven therapies, gives the below information required by Schedule 6 of the AIM Rules for Companies in connection with the UK and Global Share Incentive Plan for employees (the "SIP"), the Employee Share Option Plan (the "ESOP") and the Unapproved Share Option Plan (the "USOP") which includes long term incentive awards.
|
Name of applicant: |
Diaceutics PLC |
|||
|
Name of scheme: |
UK and Global Share Incentive Plan for employees (the "SIP"), the Employee Share Option Plan (the "ESOP") and the Unapproved Share Option Plan (the "USOP") which includes long-term incentive awards. |
|||
|
Period of return: |
From: |
7 April 2026 |
To: |
6 October 2026 |
|
Balance under scheme from previous return: |
1,233,063 Ordinary Shares of £0.002 each |
|||
|
The amount by which the block scheme has been increased, if the scheme has been increased since the date of the last return: |
N/A |
|||
|
Number of securities issued/allotted under schemes during period: |
316,969 Ordinary Shares
|
|||
|
Balance under scheme not yet issued/allotted at end of period |
916,094 Ordinary Shares |
|||
|
Number and class of securities originally listed and the date of admission |
1,500,000 Ordinary Shares on 6 October 2023 |
|||
|
Total number of securities in issue at the end of the period |
85,234,252 Ordinary Shares of £0.002 each |
|||
|
Name of contact: |
Nick Roberts |
|||
|
Telephone number of contact: |
As below |
|||
Enquiries:
|
Diaceutics PLC |
|
|
Nick Roberts, Chief Financial Officer |
Tel: +44 (0)28 9040 6500
|
|
|
|
|
Canaccord Genuity Limited (Nomad & Broker) |
Tel: +44 (0)20 7523 8000 |
|
Simon Bridges, Andrew Potts, Harry Rees |
|
About Diaceutics
At Diaceutics, our mission is to redefine commercialization for diagnostic-driven therapies, so every eligible patient is found, diagnosed and receives the right therapy at the right time. Since 2005, we have combined diagnostic intelligence, expert insight and targeted engagement to help biopharma teams see where patients are being missed and close the gaps between testing, treatment decisions and therapy adoption. Today, we work with 21 of the top 30 pharma companies, and the therapies we support touch 1 in 10 American lives. We envision a future where precision is not the privilege of the few, but the standard for all.